Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.

Maxime DougadosChristina Charles-SchoemanZoltán SzekaneczJon T GilesSteven R YtterbergDeepak L BhattGary G KochIvana VranicJoseph WuCunshan WangKenneth KwokSujatha MenonCarol A ConnellArne YndestadJose L RivasMaya H Buch

Published in: Annals of the rheumatic diseases (2023)

Keyphrases

cardiovascular events
rheumatoid arthritis
coronary artery disease
cardiovascular disease
disease activity
risk factors
ankylosing spondylitis
study protocol
randomized controlled trial
emergency department
type diabetes
clinical trial
ulcerative colitis
adverse drug